FDA Clearance Tracker · P110042-S169
Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)
Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2022
Approved
Time to decision
23 days
Received Apr 25, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P110042-S169
- Device name
- Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)
- Applicant
- Boston Scientific Corporation
- Applicant location
- St Paul, MN
- Received
- Apr 25, 2022
- Decided
- May 18, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P110042
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for updated labeling to include a clinical summary for the S-ICD Post Approval Study.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.